Phio Pharmaceuticals Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Phio Pharmaceuticals Corp. on February 10, 2026. The report addresses Item 8.01 (Other Events) regarding the formal conclusion of the Safety Medical Committee's review of the Company's Phase 1b clinical trial for the investigational drug PH-762.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial updates and does not contain financial statements or performance metrics.
Material Changes
The material event reported is the announcement of the Safety Medical Committee's formal conclusion regarding the Phase 1b clinical trial of PH-762. The filing also references updates concerning the trial's response rates, with full details contained in the attached press release (Exhibit 99.1).
Guidance, Outlook, and Risks
The filing does not provide specific forward-looking guidance, financial outlook, or a detailed discussion of risks beyond the context of the clinical trial results. Management commentary is limited to the issuance of the press release regarding the trial's safety and response data.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) for specific details on the Safety Medical Committee's conclusions.
- Verify the specific response rates and safety data for PH-762 mentioned in the clinical trial update.
- Confirm the next steps for the PH-762 development program as outlined in the press release.